B7H4 pripada porodici B7 (vidi CD80; MIM 112203) kostimulatornih proteina. Ovi proteini se eksprimiraju na površini antigen-prezentirajućih ćelija i stupaju u interakciju sa ligandima (npr. CD28; MIM 186760) na T-limfocitima (prema OMIM)[7]
Maruyama K, Sugano S (januar 1994). "Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides". Gene. 138 (1–2): 171–4. doi:10.1016/0378-1119(94)90802-8. PMID8125298.
Suzuki Y, Yoshitomo-Nakagawa K, Maruyama K, Suyama A, Sugano S (oktobar 1997). "Construction and characterization of a full length-enriched and a 5'-end-enriched cDNA library". Gene. 200 (1–2): 149–56. doi:10.1016/S0378-1119(97)00411-3. PMID9373149.
Watanabe N, Gavrieli M, Sedy JR, Yang J, Fallarino F, Loftin SK, Hurchla MA, Zimmerman N, Sim J, Zang X, Murphy TL, Russell JH, Allison JP, Murphy KM (juli 2003). "BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1". Nature Immunology. 4 (7): 670–9. doi:10.1038/ni944. PMID12796776. S2CID11943145.
Salceda S, Tang T, Kmet M, Munteanu A, Ghosh M, Macina R, Liu W, Pilkington G, Papkoff J (maj 2005). "The immunomodulatory protein B7-H4 is overexpressed in breast and ovarian cancers and promotes epithelial cell transformation". Experimental Cell Research. 306 (1): 128–41. doi:10.1016/j.yexcr.2005.01.018. PMID15878339.
Simon I, Katsaros D, Rigault de la Longrais I, Massobrio M, Scorilas A, Kim NW, Sarno MJ, Wolfert RL, Diamandis EP (august 2007). "B7-H4 is over-expressed in early-stage ovarian cancer and is independent of CA125 expression". Gynecologic Oncology. 106 (2): 334–41. doi:10.1016/j.ygyno.2007.03.035. PMID17498784.
Miyatake T, Tringler B, Liu W, Liu SH, Papkoff J, Enomoto T, Torkko KC, Dehn DL, Swisher A, Shroyer KR (juli 2007). "B7-H4 (DD-O110) is overexpressed in high risk uterine endometrioid adenocarcinomas and inversely correlated with tumor T-cell infiltration". Gynecologic Oncology. 106 (1): 119–27. doi:10.1016/j.ygyno.2007.03.039. PMID17509674.